Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy: data from the International Severe Asthma Registry (ISAR)

Mohsen Sadatsafavi; Ruth B Murray; Nasloon  Ali; Trung N Tran; David Price; ISAR FIRE Working Group

doi:10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1614

Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy: data from the International Severe Asthma Registry (ISAR)

Mohsen Sadatsafavi, Ruth B Murray, Nasloon Ali, Trung N Tran, David Price, ISAR FIRE Working Group

Research output: Contribution to journal › Abstract › peer-review

5 Downloads (Pure)

Abstract

Approximately one-third of severe asthma patients are eligible for both anti-IgE and anti-IL-5/5R therapy. However, it is not clear whether one class of biologic works better than the other amongst patients eligible for both.

Original language	English
Article number	A1614
Number of pages	1
Journal	American Journal of Respiratory and Critical Care Medicine
Volume	203
Early online date	19 May 2021
DOIs	https://doi.org/10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1614
Publication status	Published - 2021
Event	ATS International Conference Committee: ATS 2021 - Virtual event Duration: 14 May 2021 → 19 May 2021 https://conference.thoracic.org/

Access to Document

10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1614Licence: Unspecified

Sadastsafavi_et_al_ATS_WorldwideCharacterizationOfSevereAsthma_AAM
Originally Published in: [Authors]. [Article Title]. [Journal Name] [Year];[Volume]:[Pages]. DOI: [Number] Copyright ©2021 by the American Thoracic Society The final publication is available at [Link].
Accepted author manuscript, 425 KBLicence: Other

Cite this

Sadatsafavi, M., Murray, R. B., Ali, N., Tran, T. N., Price, D., & ISAR FIRE Working Group (2021). Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy: data from the International Severe Asthma Registry (ISAR). American Journal of Respiratory and Critical Care Medicine, 203, [A1614]. https://doi.org/10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1614

Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy : data from the International Severe Asthma Registry (ISAR). / Sadatsafavi, Mohsen; Murray, Ruth B; Ali, Nasloon ; Tran, Trung N; Price, David; ISAR FIRE Working Group.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 203, A1614, 2021.

Research output: Contribution to journal › Abstract › peer-review

Sadatsafavi, M, Murray, RB, Ali, N, Tran, TN, Price, D & ISAR FIRE Working Group 2021, 'Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy: data from the International Severe Asthma Registry (ISAR)', American Journal of Respiratory and Critical Care Medicine, vol. 203, A1614. https://doi.org/10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1614

Sadatsafavi M, Murray RB, Ali N, Tran TN, Price D, ISAR FIRE Working Group. Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy: data from the International Severe Asthma Registry (ISAR). American Journal of Respiratory and Critical Care Medicine. 2021;203. A1614. https://doi.org/10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1614

@article{2e6dbebdb338444d9d8fc2f3e215da4f,

title = "Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy: data from the International Severe Asthma Registry (ISAR)",

abstract = "Approximately one-third of severe asthma patients are eligible for both anti-IgE and anti-IL-5/5R therapy. However, it is not clear whether one class of biologic works better than the other amongst patients eligible for both.",

author = "Mohsen Sadatsafavi and Murray, {Ruth B} and Nasloon Ali and Tran, {Trung N} and David Price and {ISAR FIRE Working Group}",

note = "Funding: ISAR is conducted by OPC Global, and co-funded by OPC Global and AstraZeneca.; ATS International Conference Committee : ATS 2021 ; Conference date: 14-05-2021 Through 19-05-2021",

year = "2021",

doi = "10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1614",

language = "English",

volume = "203",

journal = "American Journal of Respiratory and Critical Care Medicine",

issn = "1073-449X",

publisher = "American Thoracic Society - AJRCCM",

url = "https://conference.thoracic.org/",

}

TY - JOUR

T1 - Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy

T2 - ATS International Conference Committee

AU - Sadatsafavi, Mohsen

AU - Murray, Ruth B

AU - Ali, Nasloon

AU - Tran, Trung N

AU - Price, David

AU - ISAR FIRE Working Group

N1 - Funding: ISAR is conducted by OPC Global, and co-funded by OPC Global and AstraZeneca.

PY - 2021

Y1 - 2021

N2 - Approximately one-third of severe asthma patients are eligible for both anti-IgE and anti-IL-5/5R therapy. However, it is not clear whether one class of biologic works better than the other amongst patients eligible for both.

AB - Approximately one-third of severe asthma patients are eligible for both anti-IgE and anti-IL-5/5R therapy. However, it is not clear whether one class of biologic works better than the other amongst patients eligible for both.

U2 - 10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1614

DO - 10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1614

M3 - Abstract

VL - 203

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

M1 - A1614

Y2 - 14 May 2021 through 19 May 2021

ER -

Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy: data from the International Severe Asthma Registry (ISAR)

Abstract

Access to Document

Fingerprint

Cite this